Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 126 pages | ID: F2B320C8FDDBEN
Global Markets Direct

Abstracts

Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome – Drugs In Development, 2022, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 6, 1, 27 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Fragile X Syndrome – Overview
Fragile X Syndrome – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fragile X Syndrome – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fragile X Syndrome – Companies Involved in Therapeutics Development
Fragile X Syndrome – Drug Profiles
Fragile X Syndrome – Dormant Projects
Fragile X Syndrome – Discontinued Products
Fragile X Syndrome – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fragile X Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fragile X Syndrome – Pipeline by Actinogen Medical Ltd, 2022
Fragile X Syndrome – Pipeline by Allos Pharma Inc, 2022
Fragile X Syndrome – Pipeline by Anavex Life Sciences Corp, 2022
Fragile X Syndrome – Pipeline by Anima Biotech Inc, 2022
Fragile X Syndrome – Pipeline by Astellas Pharma Inc, 2022
Fragile X Syndrome – Pipeline by Autifony Therapeutics Ltd, 2022
Fragile X Syndrome – Pipeline by Avekshan LLC, 2022
Fragile X Syndrome – Pipeline by Cognosetta Inc, 2022
Fragile X Syndrome – Pipeline by Confluence Pharmaceuticals LLC, 2022
Fragile X Syndrome – Pipeline by Connecta Therapeutics SL, 2022
Fragile X Syndrome – Pipeline by DRI Biosciences Corp, 2022
Fragile X Syndrome – Pipeline by Epigen Biosciences Inc, 2022
Fragile X Syndrome – Pipeline by GEXVal Inc, 2022
Fragile X Syndrome – Pipeline by GSK plc, 2022
Fragile X Syndrome – Pipeline by Healx Ltd, 2022
Fragile X Syndrome – Pipeline by Hua Medicine Shanghai Ltd, 2022
Fragile X Syndrome – Pipeline by Jazz Pharmaceuticals Plc, 2022
Fragile X Syndrome – Pipeline by Lysogene SAS, 2022
Fragile X Syndrome – Pipeline by Neuren Pharmaceuticals Ltd, 2022
Fragile X Syndrome – Pipeline by Neurochlore, 2022
Fragile X Syndrome – Pipeline by NeuroNascent Inc, 2022
Fragile X Syndrome – Pipeline by Novartis AG, 2022
Fragile X Syndrome – Pipeline by Paxmedica Inc, 2022
Fragile X Syndrome – Pipeline by Pilz Bioscience Corp, 2022
Fragile X Syndrome – Pipeline by Prilenia Therapeutics Development Ltd, 2022
Fragile X Syndrome – Pipeline by Prous Institute for Biomedical Research SA, 2022
Fragile X Syndrome – Pipeline by Puretech Health Plc, 2022
Fragile X Syndrome – Pipeline by Quris Technologies Ltd, 2022
Fragile X Syndrome – Pipeline by Recursion Pharmaceuticals Inc, 2022
Fragile X Syndrome – Pipeline by RespireRx Pharmaceuticals Inc, 2022
Fragile X Syndrome – Pipeline by Sentinel Oncology Ltd, 2022
Fragile X Syndrome – Pipeline by Synaptogenix Inc, 2022
Fragile X Syndrome – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Fragile X Syndrome – Pipeline by Taysha Gene Therapies Inc, 2022
Fragile X Syndrome – Pipeline by Tetra Therapeutics, 2022
Fragile X Syndrome – Pipeline by Triplet Therapeutics Inc, 2022
Fragile X Syndrome – Pipeline by Zynerba Pharmaceuticals Inc, 2022
Fragile X Syndrome – Dormant Projects, 2022
Fragile X Syndrome – Dormant Projects, 2022 (Contd..1)
Fragile X Syndrome – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fragile X Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022